{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:53:08Z","timestamp":1782636788383,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00464-025-12107-3","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T19:11:29Z","timestamp":1756149089000},"page":"7191-7201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The enhanced pathological response from additional immunotherapy improved recurrence-free survival for esophageal squamous cell carcinoma: a multi-center cohort study"],"prefix":"10.1007","volume":"39","author":[{"given":"Shuhan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunkui","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqiang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"12107_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"12107_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.734581","volume":"12","author":"R Huang","year":"2022","unstructured":"Huang R, Qiu Z, Zheng C, Zeng R, Chen W, Wang S, Li E, Xu Y (2022) Neoadjuvant therapy for locally advanced Esophageal cancers. Front Oncol 12:734581","journal-title":"Front Oncol"},{"issue":"1","key":"12107_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68\u201374","journal-title":"Ann Surg Oncol"},{"key":"12107_CR4","doi-asserted-by":"crossref","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, Group C (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074\u20132084","DOI":"10.1056\/NEJMoa1112088"},{"issue":"27","key":"12107_CR5","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D\u2019Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J, Group AMETSC (2018) Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 36(27):2796\u20132803","journal-title":"J Clin Oncol"},{"key":"12107_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.836338","volume":"13","author":"ZN Hong","year":"2022","unstructured":"Hong ZN, Gao L, Weng K, Huang Z, Han W, Kang M (2022) Safety and feasibility of esophagectomy following combined immunotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score matching analysis. Front Immunol 13:836338","journal-title":"Front Immunol"},{"issue":"8","key":"12107_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00262-025-04099-9","volume":"74","author":"S Deng","year":"2025","unstructured":"Deng S, Wang Q, Li Y, Zhang R, Li J, Zhang Y, Cai Y, Sun W, Chang J, Zhang N, Zhang L. Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2025;74(8):243.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"12107_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ, Investigators K (2024) Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 25(2):212\u2013224","journal-title":"Lancet Oncol"},{"issue":"1","key":"12107_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13643-025-02765-8","volume":"14","author":"M Wang","year":"2025","unstructured":"Wang M, Dong W, Wu G, Zhang B, Lai T, Liu A, Sun Q. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II-IVa esophageal cancer: a network meta-analysis. Syst Rev. 2025 Jan 27;14(1):26.","journal-title":"Syst Rev"},{"key":"12107_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L, group O-s (2022) Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 377:e068714","journal-title":"BMJ"},{"issue":"7","key":"12107_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/ijc.35261","volume":"156","author":"J Wang","year":"2025","unstructured":"Wang J, Li B, Zhang Y, Luo X, Zhang Y, Li H, Pan Y, Shao L, Zheng S, Yuan C, Li Y, Zheng Q, Sun S, Zhao W, Sun Y Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial. Int J Cancer. 2025;156(7):1429-1438.","journal-title":"Int J Cancer"},{"issue":"10","key":"12107_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH, Investigators ES-s (2021) Effect of camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10):916\u2013925","journal-title":"JAMA"},{"key":"12107_CR13","doi-asserted-by":"publisher","unstructured":"Yaozhong Zhang, Huazhen Du, Na Wang, Lei Wang, Yajie Huang (2024) An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis. BMC Cancer 24(1) https:\/\/doi.org\/10.1186\/s12885-024-11879-6","DOI":"10.1186\/s12885-024-11879-6"},{"issue":"2","key":"12107_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.109500","volume":"51","author":"Z Hong","year":"2025","unstructured":"Hong Z, Xie S, Xu H, Ke S, Liu W, Huang S, Chen S, Xie J, Xu J, Kang M (2025) Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy\/chemoimmunotherapy: a multi-center cohort study. Eur J Surg Oncol 51(2):109500","journal-title":"Eur J Surg Oncol"},{"key":"12107_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052542","volume":"13","author":"L Xu","year":"2022","unstructured":"Xu L, Wei XF, Li CJ, Yang ZY, Yu YK, Li HM, Xie HN, Yang YF, Jing WW, Wang Z, Kang XZ, Zhang RX, Qin JJ, Xue LY, Bi N, Chen XK, Li Y (2022) Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Front Immunol 13:1052542","journal-title":"Front Immunol"},{"issue":"24","key":"12107_CR16","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/1759-7714.15024","volume":"14","author":"S Wang","year":"2023","unstructured":"Wang S, Di S, Lu J, Xie S, Yu Z, Liang Y, Gong T (2023) (18) F-FDG PET\/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma. Thorac Cancer 14(24):2338\u20132349","journal-title":"Thorac Cancer"},{"issue":"1","key":"12107_CR17","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1038\/s41598-024-54371-8","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Zhu L, Tang M, Huang X, Gu C, He C, Lv X, Hu J (2024) Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma. Sci Rep 14(1):5523","journal-title":"Sci Rep"},{"issue":"5","key":"12107_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00432-024-05793-4","volume":"150","author":"H Lv","year":"2024","unstructured":"Lv H, Zhang F, Huang C, Xu S, Li J, Sun B, Gai C, Liu Z, Wang M, Li Z, Tian Z (2024) Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 150(5):260","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"12107_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00432-024-06004-w","volume":"150","author":"P Wang","year":"2024","unstructured":"Wang P, Chen Y, Lei M, He H, Zhang D, Lin J, Lin H, Wei W, Chen P, Zhuang F, Chen W, Zhou H, Gao P, Liu S, Wang F (2024) Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis. J Cancer Res Clin Oncol 150(10):477","journal-title":"J Cancer Res Clin Oncol"},{"key":"12107_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970534","volume":"13","author":"SW Jing","year":"2022","unstructured":"Jing SW, Zhai C, Zhang W, He M, Liu QY, Yao JF, Wang R, Tian ZQ, Wang J, Liu JF (2022) Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: a propensity score matching. Front Immunol 13:970534","journal-title":"Front Immunol"},{"issue":"5","key":"12107_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","volume":"156","author":"H Wang","year":"2021","unstructured":"Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN (2021) Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs. neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg 156(5):444\u2013451","journal-title":"JAMA Surg"},{"issue":"2","key":"12107_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, Zhu JY, Yin J, Shen YX, Zeng ZC, Jiang DX, Hou YY, Du M, Lian CH, Zhao Q, Jiang HJ, Gong L, Li ZG, Liu J, Xie DY, Li WF, Chen C, Zheng B, Chen KN, Dai L, Liao YD, Li K, Li HC, Zhao NQ, Tan LJ (2023) Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol 34(2):163\u2013172","journal-title":"Ann Oncol"},{"key":"12107_CR23","volume":"42","author":"N Fan","year":"2021","unstructured":"Fan N, Wang Z, Zhou C, Bludau M, Contino G, Zhao Y, Bruns C (2021) Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: a network meta-analysis. E Clin Med 42:101183","journal-title":"E Clin Med"},{"issue":"8","key":"12107_CR24","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1245\/s10434-023-14809-1","volume":"31","author":"YY Wu","year":"2024","unstructured":"Wu YY, Dai L, Yang YB, Yan WP, Cheng H, Fan MY, Gao YM, Chen KN (2024) Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery. Ann Surg Oncol 31(8):5047\u20135054","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"12107_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/imt-2017-0052","volume":"9","author":"H Zheng","year":"2017","unstructured":"Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS (2017) Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 9(11):913\u2013927","journal-title":"Immunotherapy"},{"key":"12107_CR26","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3389\/fimmu.2018.02100","volume":"9","author":"C Grasselly","year":"2018","unstructured":"Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C (2018) The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent. Front Immunol 9:2100","journal-title":"Front Immunol"},{"key":"12107_CR27","doi-asserted-by":"publisher","first-page":"1452195","DOI":"10.3389\/fimmu.2024.1452195","volume":"15","author":"C Fu","year":"2024","unstructured":"Fu C, Du H, Wang Q, Zhu W, Bian G, Zhong Z, Wang Y, Cao L (2024) Case report: a golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib. Front Immunol 15:1452195","journal-title":"Front Immunol"},{"issue":"4","key":"12107_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s10388-024-01070-y","volume":"21","author":"S Hori","year":"2024","unstructured":"Hori S, Yamasaki M, Yamamoto N, Harino T, Momose K, Yamashita K, Tanaka K, Sugimura K, Makino T, Takeno A, Shiraishi O, Motoori M, Miyata H, Kimura Y, Hirao M, Yasuda T, Yano M, Doki Y (2024) The impact of time to postoperative recurrence on the prognosis of patients with esophageal cancer post recurrence: exploratory analysis of OGSG 1003. Esophagus 21(4):472\u2013483","journal-title":"Esophagus"},{"issue":"3","key":"12107_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu J, Liu Z, Zhu L, Chen H, Yu B, Zhang R, Shao J, Zhang M, Li C, Li Z (2024) Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg 167(3):838-847 e831","journal-title":"J Thorac Cardiovasc Surg"},{"key":"12107_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082066","author":"J Lindenmann","year":"2020","unstructured":"Lindenmann J, Fediuk M, Fink-Neuboeck N, Porubsky C, Pichler M, Brcic L, Anegg U, Balic M, Dandachi N, Maier A, Smolle M, Smolle J, Smolle-Juettner FM (2020) Hazard curves for tumor recurrence and tumor-related death following esophagectomy for esophageal cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12082066","journal-title":"Cancers (Basel)"},{"issue":"2","key":"12107_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s10388-021-00899-x","volume":"19","author":"ZN Hong","year":"2022","unstructured":"Hong ZN, Zhang Z, Chen Z, Weng K, Peng K, Lin J, Kang M (2022) Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching. Esophagus 19(2):224\u2013232","journal-title":"Esophagus"},{"issue":"5","key":"12107_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","volume":"160","author":"X Guo","year":"2025","unstructured":"Guo X, Chen C, Zhao J, Wang C, Mei X, Shen J, Lv H, Han Y, Wang Q, Lv J, Chen H, Yan X, Liu Z, Zhang Z, Zhong Q, Jiang Y, Xu L, Li X, Qian D, Ma D, Ye M, Wang C, Wang Z, Lin J, Tian Z, Leng X, Li Z (2025) Neoadjuvant chemoradiotherapy vs. chemoimmunotherapy for esophageal squamous cell carcinoma. JAMA Surg 160(5):565\u2013574","journal-title":"JAMA Surg"},{"issue":"1","key":"12107_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12957-023-02915-z","volume":"21","author":"D Cheng","year":"2023","unstructured":"Cheng D, Zhao W, Chen R, Li D, Tang S, Fang C, Ji M (2023) Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma. World J Surg Oncol 21(1):33","journal-title":"World J Surg Oncol"},{"issue":"9","key":"12107_CR34","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, Liu S, Chen Y, Jiang H, Zhang C, Kang M, Lin J, Li H, Li C, Tian H, Li L, Fu J, Zhang Y, Ma J, Wang X, Fu M, Yang H, Yang Z, Han Y, Chen L, Tan L, Dai T, Liao Y, Zhang W, Li B, Chen Q, Guo S, Qi Y, Wei L, Li Z, Tian Z, Kang X, Zhang R, Li Y, Wang Z, Chen X, Hou Z, Zheng R, Zhu W, He J, Li Y (2024) Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med 30(9):2549\u20132557","journal-title":"Nat Med"},{"issue":"1","key":"12107_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7150\/jca.102215","volume":"16","author":"Y Gan","year":"2025","unstructured":"Gan Y, Bao T, Tang Z, Cheng C, Zhu H (2025) Analysis of the short-term efficacy of 2 versus 3 cycles of neoadjuvant immunotherapy combined with chemotherapy in patients with esophageal squamous cell carcinoma. J Cancer 16(1):279\u2013287","journal-title":"J Cancer"},{"issue":"11","key":"12107_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41416-022-01726-5","volume":"126","author":"T Makino","year":"2022","unstructured":"Makino T, Yamasaki M, Tanaka K, Yamashita K, Urakawa S, Ishida T, Shiraishi O, Sugimura K, Miyata H, Motoori M, Fujitani K, Takeno A, Hirao M, Kimura Y, Satoh T, Yano M, Eguchi H, Doki Y, Yasuda T (2022) Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. Br J Cancer 126(11):1555\u20131562","journal-title":"Br J Cancer"},{"issue":"10","key":"12107_CR37","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.21037\/jtd-24-1365","volume":"16","author":"J He","year":"2024","unstructured":"He J, Liang G, Yu H, Shen W, Pimiento JM, Anker CJ, Koyanagi K, Liu J, Hu J (2024) Two versus three to four cycles of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice. J Thorac Dis 16(10):6999\u20137015","journal-title":"J Thorac Dis"},{"key":"12107_CR38","doi-asserted-by":"publisher","first-page":"1453176","DOI":"10.3389\/fimmu.2024.1453176","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai H, Chen L, Huang J, Ma H, Zhang S, Zhong K, Yang D, Sun J, Liu H, Song R (2024) Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma. Front Immunol 15:1453176","journal-title":"Front Immunol"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-025-12107-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-025-12107-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-025-12107-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:36:44Z","timestamp":1763145404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-025-12107-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["12107"],"URL":"https:\/\/doi.org\/10.1007\/s00464-025-12107-3","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shuhan Xie, Hui Xu, Jinxin Xu, Zilu Tang, Shijie Huang, Jinbiao Xie, Rongyu Xu, Sunkui Ke, Hai Zhang, and Mingqiang Kang have no conflict of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Following the Declaration of Helsinki guidelines, the study was sanctioned by the Institutional Review Board and received approval from our institution\u2019s Ethics Committee (Ethics No. 2025KY039).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}